Login to Your Account

Other News To Note

Tuesday, June 28, 2011
Sangamo BioSciences Inc., of Richmond, Calif., said Nature published a preclinical study that demonstrated permanent functional correction of the gene that causes hemophilia B by the systemic delivery of zinc finger nucleases. The study represents an advance in the development and systemic delivery of ZFP therapeutics and proof of concept for ZFN-based gene-editing to treat hemophilia and other monogenic diseases.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription